The study, published Aug. 9 in Cell, treated 15 patients with Pseudomonas aeruginosa infections using a virus called PASA16 and antibiotics. Patients received a once- to twice-daily regimen for a minimum of eight days.
Of patients, 13 had good clinical outcomes, suggesting the virus could help patients for whom traditional treatments have failed previously, the authors said. The treatment had few minor side effects.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.